Register or Sign in
to unlock feature

you are not authorized to read this article.

Login or register your account to get full access to the tableting technology platform.

Login Register
Please verify your account
Please confirm your email address to validate your registration. Follow the link on email received to verify your email adress.
Re-send verification email
Please complete your registration
You're logged in but you didn't complete your registration.
Complete my registration
Exclusive content

You are not authorized to read this article.

mystylone subscription is required to view this content.

Login Register
Close search
  • Resources
  • Products & Services
    • Compaction Simulators
    • R&D / Process Support
  • Events
  • About
  • Contact Us
  • Sign in
Resources
  1. Home /
  2. Resources /
  3. Newsfeeds /
  4. Identify your lead solid form early to reduce timelines and downstream costs
NEWSFEEDS

Identify your lead solid form early to reduce timelines and downstream costs

April 22, 2025
Remove from favorites
Add to favorites

Identifying the lead solid form of an active pharmaceutical ingredient (API) early in drug development can significantly streamline timelines and reduce downstream costs. Lonza's recent webinar, "Solid Form Screening of Active Pharmaceutical Ingredients," emphasized the importance of this approach. Abhijeet S. Sinha, Manager of Solid Form Services at Lonza, outlined various solid forms and the screening workflows essential for selecting the optimal form.
Key Phases in Solid Form Screening:

- Early Development: Conduct polymorph, salt, and cocrystal screenings, along with comprehensive characterization and risk assessments, to identify the lead crystalline form

- Later Development: Perform additional risk assessments and refine crystallization process development to ensure consistency and scalability


Expert Insights:

- Selecting the Preferred Solid Form: The choice depends on manufacturability, stability, and solubility enhancement. For polymorphs, the thermodynamically stable form is preferred. For salts and cocrystals, considerations include manufacturability and stability

- Applicability of Salt Screening: Salt screening is suitable for APIs with ionizable functional groups, such as carboxylic acids, amines, and pyridines.

- Considering Amorphous Forms: If crystalline forms don't meet solubility targets, alternative enabled forms like salts, cocrystals, or amorphous forms may be considered

By dedicating resources to solid form screening early, pharmaceutical developers can enhance drug performance and streamline the development process.

Read more
Tablet pharma white on background
active pharmaceutical ingredient manufacturability solid form oral solid dosage form screening
Contributor(s):
Share Copied!
Comments

No comments posted yet.

Add a comment

Articles you may like

5 best practices to ensure quality active pharmaceutical ingredients

Five best practices to ensure quality active pharmaceutical ingredients

first_published_at:May 31, 2024, 8:43 a.m. / date_published:None
Newsfeeds - 31/05/2024 -
The global market for active pharmaceutical ingredients (API) was valued at approximately $173 billion in 2020 and is projected to reach $286 billion by 2027, driven by the demand for …

Image improving active pharmaceutical ingredient formulation by hot melt extrusion

Improving active pharmaceutical ingredient formulation by hot melt extrusion

first_published_at:June 10, 2024, 2:45 p.m. / date_published:None
Newsfeeds - 10/06/2024 -
This poster, presented at the PBP World Meeting 2024 in Vienna, explores the integration of AI and big data in pharmaceutical research, revolutionizing drug discovery. Despite advancements, challenges arise due …

close-up- pharma-powder-bowl-

Five best practices to ensure quality active pharmaceutical ingredients

first_published_at:May 16, 2025, 1:46 p.m. / date_published:None
Newsfeeds - 16/05/2025 -
The global market for active pharmaceutical ingredients (APIs) is growing rapidly, projected to rise from $173 billion in 2020 to $286 billion by 2027, driven by demand for COVID-19 vaccines, …

More

Related products

Take_off_sensor

Linear ejection device

MEDELPHARM
Introducing the linear ejection device, a versatile accessory designed to seamlessly integrate with the STYL'One …
Accessory_Evo_TabInTab_16

Tab-in-tab device

MEDELPHARM
Tab-in-tab technology (press-coated tablets) showcases multiple advantages including enhanced drug stability, modified release profiles, taste …
Accessory_Evo_gravity_feeder_3

Gravity feeder - STYL'One Evo

MEDELPHARM
The primary function of compaction simulators is to provide reliable data from which information can …
Tapping Feeder - STYL'One Evo 4

Tapping feeder - STYL'One Evo

MEDELPHARM
The primary function of compaction simulators is to provide reliable data from which information can …
Paddle Force Feeder - STYL'One Nano 1

Paddle force feeder - STYL'One Nano

MEDELPHARM
The primary function of compaction simulators is to provide reliable data from which information can …
illustration STYL'One Mist manual lubrication

Manual external lubrication

MEDELPHARM
In development, external lubrication enables the characterization of the compaction behavior of pure APIs or …
Evolution_resize

STYL'One Evo

MEDELPHARM
The STYL’One Evo is a highly versatile compaction simulator designed to support pharmaceutical and nutraceutical …
0.STYLOne_Nano_y66g4Pc_resize

STYL'One Nano

MEDELPHARM
The STYL’One Nano is a compact, benchtop compaction simulator designed for early-stage tablet formulation and …
STYLOne_EVO_OEB3_sans_fond_mod_resize

STYL'One Evo DryCon®

MEDELPHARM
The STYL’One Evo is designed to work under negative pressure and as such, the standard …
STYLONE_EVO_OEB5_transparent_apxkk5N_resize

STYL'One Evo WipCon®

MEDELPHARM
The STYL’One Evo is designed to work under negative pressure and as such, the standard …
laptop laboratory gloves

Looking for additional information?

Let us help you

Contact our experts

GENERAL

  • Terms of service
  • Privacy Policy
  • Cookie Policy
  • About
  • Contact us

Account

  • Login

Follow us on

© 2025 Medelpharm